Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,747

Document Document Title
WO/2018/026781A1
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/...  
WO/2017/127833A1
The present invention provides methods, devices, and compositions to rapidly detect analytes, including small analytes, using a lateral flow device. Described herein is such a lateral flow device that can detect and quantify vitamin D in...  
WO/2017/053793A1
Methods and systems for making intermediates in the synthesis of onapristone are provided. Aspects include the photoconversion of onapristone synthesis intermediates using a narrow band frequency light source.  
WO/2017/023617A1
Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylene-vitamin D3, (20S)-1α-hydroxy-2-met...  
WO/2017/014332A1
The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety...  
WO/2016/192564A1
Disclosed are a polyene compound, preparation method and use thereof. Provided in the present invention is the preparation method of a polyene compound I, comprising the following steps: under an action of a base and in an organic solven...  
WO/2016/191583A1
Disclosed are la,25-dihydroxy-24,24-difluoro-2-methylene-19-nor- vitamin D analogs of formula I and their pharmaceutical uses. These new vitamin D analogs are 19-nor-vitamin D analogs having two fluorine atom substitutions at the 24 posi...  
WO/2016/103722A1
The present invention relates to vitamin D3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesit...  
WO/2016/100892A1
It is an object of the present invention to provide methods for producing vitamin D that gives improved yields and reduced side product contamination. In various aspects, these methods provide for production of vitamin-D2 using ergostero...  
WO/2016/058472A1
Provided are a vitamin D2 and vitamin D3 eutectic crystal, a preparation method and use thereof, and a pharmaceutical composition comprising the eutectic crystal. The vitamin D2 and vitamin D3 eutectic crystal has the advantages of a hig...  
WO/2016/056610A1
 The present invention provides a method for manufacturing 7-dehydrocholesterol (7-DHC), the method being characterized by culturing, in a culture medium, a labyrinthulean micro-organism that produces 7-DHC and that has decreased stero...  
WO/2015/108058A1
 The present invention provides a method for manufacturing 7-dehydrocholesterol, the method being characterized by deleting, replacing or adding at least one base in a gene that is present on the chromosomal DNA in a parent strain and ...  
WO/2015/098152A1
The present invention is a method that is for preparing a crystallography sample for determining the molecular structure of a metabolite and that is characterized by having a step in which, by means of contacting, to a solvent solution c...  
WO/2015/018757A1
The present invention relates to novel vitamin D compounds bonded to a marker group via a linker at the C-3 stereocenter. The present invention further relates to a process for preparing these vitamin D compounds and to the use of an int...  
WO/2014/165232A1
The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.  
WO/2014/116386A1
Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitam in D3 compounds, their biological activities, and various pharmaceutical uses for these compounds. Particularly disclosed are (22E )-(24R)-2-methylene-22-dehydro-...  
WO/2014/091046A1
Versatile and functionalised intermediates for the synthesis of vitamin D and novel vitamin D derivatives. The invention provides novel intermediates for the complete synthesis of vitamin D and allows a great versatility of functional gr...  
WO/2014/024210A3
The present invention provides a novel amorphous Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a solid dispersion of doxercalciferol in combination...  
WO/2014/024210A2
The present invention provides a novel amorphous Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a solid dispersion of doxercalciferol in combination...  
WO/2013/184412A1
Disclosed are 19-nor-vitami D compounds, and specifically seco-A-2, 19-dinor- 1,25- dihydroxyvitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high activity in vivo, specifically in intestinal tissues...  
WO/2013/180882A1
Disclosed are methods of purifying the compound (20R)-19-nor-24- difluoro-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a...  
WO/2013/180880A1
Disclosed are methods of purifying the compound (20R>2-methylene-19-nor-24- difluoro-1α,25-dihydroxy vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the c...  
WO/2013/180879A1
Disclosed are methods of purifying (20R) and (20S) analogs of 2-methylene-19- nor-22-dimethyl-1α,25-dihydroxyvitamin D3 to obtain the (20R) and (20S) analogs in crystalline form. The method includes the steps of preparing a solvent of e...  
WO/2013/180881A1
Disclosed are methods of purifying the compound (20R,22R)-2-metJiylene-19- nor-22-methyl-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing th...  
WO/2013/154752A1
5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARϒ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflam...  
WO/2013/059021A1
This invention discloses 2-methylene- vitamin D analogs of formula ( I) (wherein R and X are as defined in claim 1 ), and specifically (20S)-25- hydroxy-2-methylene- vitamin D3 and (20R)-25-hydroxy-2-mcthylene-vitamin D3, as well as phar...  
WO/2013/059060A1
This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)- lα,25-dihydroxy-2-methylene-vitamin D3 as well as (5E)-(20S)-lα,25-dihydroxy-2- methylene-vitamin D3 and (20R)-lα,25-dihydroxy-2-methylene- vitamin D3, as...  
WO/2013/032740A1
A method of purifying 1α-hydroxy-20-methyl-2 -methylene- 19,24,25,26, 27- pentanorvitamin D3 to obtain 1α-hydroxy-20-methyl-2-methylene- 19,24,25, 26,27- pentanorvitamin D3 in crystalline form. The method includes the steps of preparin...  
WO/2013/032846A1
Compounds of Formula (I) are provided where R1 and R2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological ...  
WO/2013/023327A1
A new compound 1 which structure is as shown in formula 1 and its preparation method are provided. The synthesization of it is as follows: reacting (S)-2-methyl-3-hydroxy-methyl propionate as the original material with methyl metallic re...  
WO/2013/021138A3
The invention relates to yeast flakes enriched with vitamin D2, to compositions including said flakes, and to the uses thereof, as well as to a method for preparing yeast flakes enriched with vitamin D2 and to the device for implementing...  
WO/2013/012644A1
This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26, 27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydro xyvitamin D3, and pharmaceutical uses therefor. This compound e...  
WO/2013/003307A1
This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22- dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyI-24- oxo-26,27-cycIo-22-dehydro-19-nor-lα-hydroxyvitamin D3, and pharmaceutica...  
WO/2012/174095A1
This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-l a,25-diydroxy-19-nor-vitamin D3 and (20R)-3- desoxy-2-methylene-la,25-dihydroxy- 19-nor-vitamin D3 as well as pharmaceu...  
WO/2012/166938A3
Cyclopropane-containing vitamin D analogs of formulas I and IV are provided. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.  
WO/2012/166938A2
Cyclopropane-containing vitamin D analogs of formulas I and IV are provided. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.  
WO/2012/158794A1
This invention discloses N-cyclopropyl-(20R)-2 -methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-h ydroxyvitamin D3 and pharmaceutical uses therefor. This com...  
WO/2012/151420A1
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for ...  
WO/2012/122451A2
The present invention relates to Maxacalcitol polymorphs and Maxacalcitol having low residual solvent content as well as processes for their preparation. The present invention also relates to pharmaceutical compositions containing Maxaca...  
WO/2012/122451A3
The present invention relates to Maxacalcitol polymorphs and Maxacalcitol having low residual solvent content as well as processes for their preparation. The present invention also relates to pharmaceutical compositions containing Maxaca...  
WO/2012/118154A1
Provided is a compound that functions as a selective vitamin D receptor modulator and has effect selectivity or tissue selectivity that induces other effects, without inducing hypercalcemia. The compound indicated by formula (I), a solva...  
WO/2012/065050A1
This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote ...  
WO/2012/057068A1
Provided is a novel vitamin D3 derivative which is useful as a therapeutic agent for osteoporosis. Specifically provided is a vitamin D3 derivative represented by formula (1) or a pharmaceutically acceptable solvate thereof. In the formu...  
WO/2012/044689A1
A method of purifying (20R,25S)-2-methylene-l9,26-dinor-lα,25-dihydroxyvitamin D3 to obtain (20R,25S)-2-methylene-l9,26-dinor-lα,25-dihydroxyvitamin D3 in crystalline form. The method includes the steps of preparing a solvent of methan...  
WO/2011/127465A2
The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) ...  
WO/2011/127465A3
The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) ...  
WO/2011/121152A1
The present invention relates to two chiral compounds, to a method for the synthesis thereof and to the use thereof as precursors for obtaining analogues of Gemini vitamin D3. The vitamin D analogue known as Gemini, having two side chain...  
WO/2011/120162A1
1 a-hydroxy vitamin D2 (doxercalciferol) of exceptionally high purity and stability is prepared by a process involving chromatographically purifying 1 α-hydroxyvitamin D2 monoacetate, chemically removing the acetate protectant group fro...  
WO/2011/119610A3
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biologica...  
WO/2011/119610A2
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biologica...  

Matches 1 - 50 out of 3,747